Major Depressive Disorder
Higher dose of omega-3 fatty acid reduced MDD in overweight adults at 12 weeks
Eicosapentaenoic acid at a dose of 4 g per day reduced effects of major depressive disorder in overweight individuals with elevated inflammatory markers better than placebo at 12 weeks, according to a recently published study.
FDA provides guidance to Alzamend ahead of IND application for oral therapeutic
The FDA has provided guidance to biopharmaceutical company Alzamend Neuro Inc. regarding its development of an oral therapeutic to treat a range of psychological disorders.
Psilocybin for MDD clinical trial begins enrollment
Clinilabs Drug Development Corp. announced enrollment has begun in a phase 1/2a clinical trial for the use of CYB003, a novel psilocybin analog that will be evaluated for the treatment of major depressive disorder.
Dextromethorphan-bupropion effective in improving symptoms of major depressive disorder
Dextromethorphan-bupropion significantly improved symptoms for those with major depressive disorder compared with bupropion alone and produced minimal adverse effects, according to a study published in American Journal of Psychiatry.
VIDEO: Adjunctive treatment with cariprazine improved depression symptoms
NEW ORLEANS – Patients who received cariprazine in addition to their standard antidepressant showed clinical improvement for depression, Gary Sachs, MD, said at the American Psychiatric Association annual meeting.
FDA approves TMS as form of OCD treatment
The FDA has approved Neuronetics’ transcranial magnetic stimulation system, called NeuroStar, as an adjunct treatment for adults with obsessive compulsive disorder.
Psilocybin-assisted treatment for depression safe, effective through 12 months
Through 12 months, psilocybin-assisted treatment showed to be safe and effective for major depressive disorder, researchers reported in the Journal of Psychopharmacology.
Rolling submission of NDA begins for FDA on daily oral drug for depression
Sage Therapeutics and Biogen Inc. announced they have initiated a rolling submission for a New Drug Application to the FDA for zuranolone, a once-daily oral drug being developed to treat major depressive disorder.
Digital therapeutic tool improved attention, cognitive function for adults with MDD
Use of a digital therapeutic tool by adults with major depressive disorder resulted in significant improvement in attention and cognitive functioning, according to a study published in the American Journal of Psychiatry.
Comorbidities linked to treatment-resistant depression in older adults with MDD
Older adults with late-onset major depressive disorder and anxiety or substance use disorders were more likely to experience treatment-resistant depression, a study published in the Journal of Clinical Psychiatry showed.